LJPC

[setravis]

Jolly has been making a move....Volume now @ 2,017,851.......+17.50%
Breaking through the resistance @ 0.88.
Back above the 50/200-dma

Technicals
Last Price Quote is:
26.12%above 13-day EMA
25.67%above 50-day EMA
RS Rating: 68 

Fundamentals
Key Data:
Market Cap (M): $49.46 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 03/09/2006
Last Analyst Rating: Under Weight

[setravis]

Press Release Source: La Jolla Pharmaceutical Company


La Jolla Pharmaceutical Company Receives Nasdaq Extension and Completes Reverse Stock Split
Wednesday December 21, 5:00 pm ET


SAN DIEGO, Dec. 21 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company (Nasdaq: LJPC - News) announced today that Nasdaq has granted it an extension of time to comply with Nasdaq's minimum bid price rule. The extension period will allow additional time for the closing price of the Company's common stock to be at least $1.00. If the closing price is at least $1.00 for a minimum of 10 consecutive trading days on or before January 6, 2006, the Company will regain compliance with the minimum bid price rule and maintain its Nasdaq National Market listing.

The Company also announced today that it has completed its previously announced one-for-five reverse stock split. The reverse stock split was proposed, among other matters, to enable the Company to comply with the Nasdaq minimum bid price rule and was approved by the Company's stockholders on December 12, 2005 at a special meeting of stockholders.

The reverse stock split caused every five shares of the Company's outstanding common stock to convert automatically into one share of common stock. As a result, upon the effective time of stock split, the number of the Company's shares outstanding decreased by one-fifth and the price of the Company's common stock increased by five times. Effective upon the opening of the market on December 22, 2005, the Company's shares of common stock will trade on a post-reverse stock split basis on The Nasdaq National Market.

La Jolla Pharmaceutical Company is a biotechnology company developing therapeutics for antibody.mediated autoimmune diseases and inflammation afflicting several million people in the United States and Europe. The Company is developing Riquent® for the treatment of lupus kidney disease, a leading cause of sickness and death in patients with lupus. The Company is also developing small molecules to treat various other autoimmune and inflammatory conditions. The Company's common stock is traded on The Nasdaq Stock Market under the symbol LJPC. For more information about the Company, visit its Web site: http://www.ljpc.com.

Except for historical statements, this press release contains forward- looking statements. These forward-looking statements involve risks and uncertainties, and a number of factors, both foreseen and unforeseen, could cause actual results or events to differ materially from those anticipated. Readers are cautioned to not place undue reliance upon forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after the date hereof. Interested parties are urged to review the risks described in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2005, and in other reports and registration statements that we file with the Securities and Exchange Commission from time to time.




--------------------------------------------------------------------------------
Source: La Jolla Pharmaceutical Company

[setravis]

Form 8-K for LA JOLLA PHARMACEUTICAL CO


--------------------------------------------------------------------------------

21-Dec-2005

Notice of Delisting or Transfer



Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Standard; Transfer of Listing.
On December 19, 2005, La Jolla Pharmaceutical Company (the "Company") was notified by Nasdaq that it had been granted an extension of time to comply with the Nasdaq minimum bid price rule. If, on or before January 6, 2006, the closing price of the Company's common stock is at least $1.00 for a minimum of 10 consecutive trading days, the Company will regain compliance with the minimum bid price rule and maintain its listing on the Nasdaq National Market. As further discussed below, on December 21, 2005, the Company effected a one-for-five reverse stock split and its common stock will begin to trade on a post-stock split basis on December 22, 2005.
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On December 21, 2005, the Company filed a Certificate of Amendment to its Certificate of Incorporation (the "Amendment"). The Amendment was effective as of 5:00 p.m. (EST). The purpose of the Amendment was to effectuate a reverse split of the issued and outstanding common stock of the Company whereby every five shares of the Company's common stock were combined into one share of the Company's common stock. The Company's common stock will begin to trade on the Nasdaq National Market on a post-reverse stock split basis on December 22, 2005. The Company will pay cash, based on the closing price of the Company's common stock on December 20, 2005, for any fractional shares that result from the reverse stock split. The reverse stock split was approved by the board of directors of the Company on October 17, 2005 and by the Company's stockholders on December 12, 2005.
As a result of the reverse stock split, the Company's issued and outstanding common stock was reduced from approximately 162,570,378 shares to approximately 32,514,075 shares. The authorized capital of the Company was not affected by the Amendment. A copy of the Amendment is attached hereto as Exhibit 3.1. Item 9.01 Financial Statements and Exhibits.
(d) Exhibits The following exhibit is furnished with this Current Report on Form 8-K:

Exhibit
  No.                                    Description

3.1        Certificate of Amendment to Certificate of Incorporation of La Jolla
           Pharmaceutical Company, effective December 21, 2005

99.1       Press Release, dated December 21, 2005

[setravis]

Technicals
Last Price Quote is:
11.85%above 13-day EMA
18.08%above 50-day EMA
RS Rating: 72 

Fundamentals
Key Data:
Market Cap (M): $68.22 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 03/09/2006
Last Analyst Rating: Under Weight

[setravis]

LA JOLLA PHARM CO (NasdaqNM:LJPC) Delayed quote data 

After Hours (RT-ECN): 0.90  0.07 (8.43%)

Last Trade: 0.83
Trade Time: 3:59PM ET
Change:  0.02 (2.47%)
Prev Close: 0.81
Open: 0.86
Bid: 0.01 x 100
Ask: 9,000.00 x 100
1y Target Est: 2.00

  Day's Range: 0.81 - 0.87
52wk Range: 0.36 - 1.90
Volume: 890,952
Avg Vol (3m): 542,780
Market Cap: 61.55M
P/E (ttm): N/A
EPS (ttm): -0.46
Div & Yield: N/A (N/A)

[setravis]

AP
La Jolla Shares Up on Study Results
Thursday March 8, 4:39 pm ET 
La Jolla Shares Rise After Positive Results From Lupus Drug Trial


NEW YORK (AP) -- La Jolla Pharmaceutical Co. stock rose Thursday after the company reported positive results from a late stage study of Riquent, a treatment for the autoimmune disorder lupus.
Shares of La Jolla rose 97 cents, or 31 percent, to close at $4.13 on the Nasdaq Stock Market. Shares traded as high as $4.81, below the 52-week high of $5.40 set last March.


Interim results from a Phase III trial showed that higher doses of Riquent to treat systemic lupus erythematosus showed a greater reduction in certain antibodies -- a sign of clinical improvement -- than lower doses or a placebo in 101 patients.

This is a boon for the company, which found the drug -- its leading product -- wasn't sufficiently effective at lower doses.

"Higher doses also appear to result in a larger percentage of patients having greater and more consistent antibody reductions over time," La Jolla Chief Executive Deirdre Y. Gillespie said.

The positive results in the higher doses make it more likely that the ongoing Phase III trial will show positive clinical results, she said. In addition, Riquent so far has been well tolerated in the trial.

Data will be presented at the 8th International Congress on systemic lupus erythematosus in Shanghai in May.

Lupus, a chronic inflammatory disease that can cause organ malfunction, affects roughly 1.5 million people in the United States, 90 percent of whom are women.

Several drug makers are in advanced stage trials for lupus drugs. To date, no specific lupus drug has been approved in the United States.

[setravis]

"LJPC" Threads have been Merged.
Please use the search before starting new threads on a Stock Pick.
Chances are a thread already exist.
So why not post whatever you have to comment about on that pick to that thread.
"Simplicity" My fellow traders.                                    
All history on a stock pick in 1 thread is awesome.                                   
Just trying to get threads together,so we don't have a numerous amount floating around on the same stock.              
Thank You....and good luck with all your trades....make some $$$             

[setravis]

Gap up breakout......
In Play La Jolla Pharm announces positive interim antibody results from Riquent Lupus Phase 3 trial.


52wk Range: 2.77 - 4.81
Volume: 5,572,774
Avg Vol (3m): 87,227.8

Technicals
13-day EMA Cross Above 50-day MA
MACD - Bullish
Percentage Gainer

Last Price Quote is:
81.27%above 13-day MA
85.59%above 50-day MA
RS Rating: 98 

Fundamentals
Key Data:
Market Cap (M): $121.27 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: Under Weight

[ScottishTrader]

Setravis please please PLEASE tell me you picked up some LJPC shares the last few days.  It is absolutely ON FIRE!!!!

Completely missed this one - even looked at it on Friday and over the weekend.  Sheesh!!

[setravis]

Setravis please please PLEASE tell me you picked up some LJPC shares the last few days.  It is absolutely ON FIRE!!!!

Completely missed this one - even looked at it on Friday and over the weekend.  Sheesh!!

I think I have a few shares lying around.......


La Jolla Pharma Climbs, Gets Upgrade
52wk Range: 2.77 - 6.85
Volume: 7,073,443
Avg Vol (3m): 134,650

Technicals
Most Actives
Percentage Gainer

Last Price Quote is:
111.61%above 13-day MA
133.95%above 50-day MA
RS Rating: 99 

Fundamentals
Key Data:
Market Cap (M): $121.27 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: Under Weight


SeekingAlpha
La Jola Shares Continue To Surge: Caution is Warranted
Monday March 12, 12:31 pm ET


Ant & Sons submits: La Jolla Pharmaceutical Company (NasdaqGM: LJPC) reported Thursday positive interim antibody results from its ongoing double-blind, placebo-controlled randomized Phase 3 trial of Riquent, the company's drug candidate for systemic lupus erythematosus. The greater reductions in antibodies to dsDNA observed with these higher doses of Riquent imply a greater probability of obtaining positive clinical results from the Phase 3 trial.


Two years ago, the FDA gave approval for Riquent, but then requested additional tests to prove efficacy. Lupus, a chronic inflammatory disease that can cause organ malfunction, affects roughly 1.5 million people in the United States. Jill Buyon, M.D., Professor of Medicine at New York University School of Medicine added that "these are highly encouraging data which should attract attention from the lupus community since a reduction in antibodies to dsDNA is a biomarker we associate with clinical improvement."

Following the news, analysts at Pacific Growth said Friday that the company's lupus drug Riquent is likely to achieve significant results from primary endpoint in ongoing trial with top-line data seen in 2009. The firm believes the potential for United States sales of the drug as high as $378M. As a result, Pacific Growth upgraded shares of La Jolla from "neutral" to "buy."

Today, the stock is trading higher on pure momentum by $1.53, or 25.89%, to $7.44 on heavy volume of 2.5 million shares. Despite the recent news, investors should be cautious because the stock has now seen double digit percent gains in the past three trading sessions. On Thursday, the stock was higher by 24%, on Friday it was higher by 31%, and today La Jolla shares are up by another 24%.

[setravis]

AP
La Jolla Pharma Climbs, Gets Upgrade
Monday March 12, 4:18 pm ET 
La Jolla Pharmaceuticals Upgraded on Trial Results for Lupus Drug; Shares Surge 30 Percent


NEW YORK (AP) -- Shares of La Jolla Pharmaceutical Co. shot to a two-year high Monday after a Pacific Growth Equities analyst said data from a clinical trial of Riquent, its lupus treatment, was better than expected.


Analyst Liana Moussatos upgraded La Jolla shares to "Buy" from "Neutral." On Thursday, the San Diego-based company reported that lupus patients treated with 300 milligrams or 900 milligrams of Riquent per week showed significantly more improvement than those treated given just 100 milligrams per week.

"We believe this is significant as 100 mg was the highest dose tested in previous pivotal studies and the level of antibody reduction achieved with 900 mg has been correlated with potential clinical benefit," Moussatos said. We anticipate a potential top-line data release in early 2009, launch in early 2010 and potential peak U.S. sales of about $378 million."

Shares of La Jolla Pharmaceuticals gained $1.79, or 30.3 percent, to close at $7.70 on the Nasdaq Stock Market, having hit a new high of $8.14 earlier in the session. Previously, the stock traded in a 52-week range of $2.77 and $6.85.

[Ares]

LJPC moving

[brucey]

setravis----Re: LJPC...Sector: Healthcare~~~Industry: Biotechnology & Drugs
« Reply #33 on: December 21, 2005, 07:50:32 PM »
by that time LJPC was about  0.93,
It closed @7.19 last friday....

[nica33]

Insiders in action!!!!!

http://www.secform4.com/insider-trading/920465.htm

[setravis]

Back above the 13-day MA


52wk Range: 2.77 - 8.57
Volume: 2,681,707
Avg Vol (3m): 603,837

Technicals
Close Above the 13-day EMA
Percentage Gainer

Last Price Quote is:
16.70%above 13-day MA
44.90%above 50-day MA
RS Rating: 99 

Fundamentals
Key Data:
Market Cap (M): $121.27 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 05/10/2007
Last Analyst Rating: Buy